CRYO-CELL International, Inc. (CCEL) Analysts See $0.00 EPS

June 20, 2017 - By Winifred Garcia

 CRYO CELL International, Inc. (CCEL) Analysts See $0.00 EPS

Analysts expect CRYO-CELL International, Inc. (OTCMKTS:CCEL) to report $0.00 EPS on July, 10. It closed at $5.6 lastly. It is down 0.00% since June 20, 2016 and is . It has underperformed by 16.70% the S&P500.

Cryo-Cell International, Inc. is engaged in cellular processing and cryogenic storage. The company has market cap of $71.77 million. The Company’s divisions include cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacture of Prepacyte CB units, the processing technology used to process umbilical cord blood stem cells. It currently has negative earnings. The Company, in combination with its global affiliates, stores over 300,000 cord blood and cord tissue specimens around the world.

More notable recent CRYO-CELL International, Inc. (OTCMKTS:CCEL) news were published by: Prweb.com which released: “Cryo-Cell International’s New 5-Chamber Cord Blood Cryo-Bag Gives Parents …” on April 07, 2017, also Globenewswire.com with their article: “Cord Blood Banking Leader Cryo-Cell Reports Fiscal First Quarter 2017 …” published on April 14, 2017, Prweb.com published: “Cryo-Cell International Announces New Advanced Stem Cell Collection Kit That …” on March 07, 2017. More interesting news about CRYO-CELL International, Inc. (OTCMKTS:CCEL) were released by: Bizjournals.com and their article: “Cryo-Cell International files suit, suggests takeover of rival firm” published on April 03, 2015 as well as Globenewswire.com‘s news article titled: “Cryo-Cell Reports Financial Results for Fiscal 2016” with publication date: February 28, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.